Abstract
Background: To explore the correlation of serum levels of interleukin-2 (IL-2) and interferon-γ (IFN-γ) with the clinical prognosis of patients with nasopharyngeal carcinoma (NPC) and analyze the risk factors.
Methods: The clinical data of 195 NPC patients admitted to our hospital from October 2020 to October 2022 were selected for retrospective study. The patients who obtained 0 point were in good prognosis group (group g), while those who obtained 1-2 points were in poor prognosis group (group p) based on Glasgow score. The levels of serum IL-2 and IFN-γ were compared between the two groups, and the clinical values of serum IL-2 and IFN-γ in the prognosis of patients were analyzed. The clinical parameters of the patients were collected, and the risk factors affecting the prognosis of NPC were analyzed by univariate and multivariate Logistic regression.
Results: Among 195 patients, 125 were in the group g and 70 were in the group p. The levels of IL-2 and IFN-γ in the group g were higher than the group p (P<0.05). The predictive AUC (95%CI) of IL-2 and IFN-γ were 0.846 (0.791-0.902) and 0.851 (0.797-0.904), respectively (P<0.05). Logistic regression analysis showed that age, tumor diameter, clinical stages and degree of differentiation were risk factors for the prognosis of NPC patients.
Conclusion: The levels of serum IL-2 and IFN-γ are closely related to the prognosis of NPC patients, and have certain value in evaluating the prognosis of patients. The age, tumor diameter, tumor staging and degree of tumor differentiation are all risk factors affecting the prognosis of patients, which can provide a reference for the selection of clinical treatment methods and evaluation of prognosis.
Keywords
Array
Array
Array
Array
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.